#United States #New York #Rosen Law Firm #ImmunityBio #IBRX

Investors Have a Chance to Lead the ImmunityBio Class Action

In a recent announcement, the Rosen Law Firm has urged investors who purchased securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026, and March 24, 2026, to consider participating in a securities fraud class action lawsuit. This matter highlights crucial legal steps that affected investors need to undertake promptly.

The Basis for the Class Action

The class action lawsuit stemmed from allegations against ImmunityBio, Inc. concerning misleading statements and a lack of transparency regarding its product Anktiva. Allegedly, the company's leader, Patrick Soon-Shiong, significantly overstated the drug's capabilities, and as a result, the information released regarding ImmunityBio’s operations and future prospects was misleading. These circumstances led to the decline in the company's stock value once the accurate information was disclosed.

Important Deadlines to Note

Investors have been reminded that the deadline to apply as the lead plaintiff in this class action is May 26, 2026. Serving as a lead plaintiff means representing the interests of other investors within the class and guiding the litigation process. Potential claimants should act quickly to ensure their participation.

No Out-of-Pocket Fees

A significant advantage of this legal avenue is that investors may not need to incur upfront fees or costs. The Rosen Law Firm operates on a contingency fee basis, which means that compensation is covered from any recovery obtained through the lawsuit. This financial structure allows investors from various backgrounds to pursue their claims regardless of their financial situation.

How to Join the Class Action

For individuals interested in joining the class action against ImmunityBio, further details can be found on the Rosen Law Firm's website: rosenlegal.com. Interested parties can also reach out via telephone at 866-767-3653 or contact [email protected] The firm has experience representing investors globally and specifically focuses on securities class actions.

Selecting the Right Legal Representation

The Rosen Law Firm emphasizes the importance of choosing qualified legal counsel with a proven track record in securities matters. Many law firms do not have the requisite expertise and merely refer clients to others who handle litigation. Investors should be prudent when selecting legal representation to ensure their interests are adequately protected.

Conclusion

As the deadline approaches, affected investors are encouraged to step forward and consider their options regarding the ImmunityBio class action lawsuit. Engaging in this legal action could potentially enable recovery for damages incurred during the specified time frame, particularly if the claims against the company prove to be valid.

Investors should stay informed about any updates related to the case and maintain communication with their legal representatives to ensure they do not miss important deadlines. Following legal channels is crucial for those who seek compensation for their investments in ImmunityBio amidst these evolving legal challenges.